GlaxoSmithKline's new medication has been approved in China for the treatment of adult chronic obstructive pulmonary disease.

On December 22, GlaxoSmithKline China announced that the China National Medical Products Administration has approved Nucala for the maintenance treatment of adult patients with chronic obstructive pulmonary disease characterized by elevated blood eosinophils that are not adequately controlled.